UnitedHealth Group Antidilutive Securities Excluded from EPS increased by 50.0% to 18M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 200.0%, from 6M to 18M. Over 4 years (FY 2021 to FY 2025), Antidilutive Securities Excluded from EPS shows an upward trend with a 67.3% CAGR.
An increase suggests that a larger portion of outstanding equity instruments are currently 'out-of-the-money' or otherwise antidilutive, while a decrease may indicate that more instruments have become dilutive as the share price rises.
This metric represents the count of potential common shares, such as stock options or convertible instruments, that are...
Most large-cap companies report this figure in their EPS reconciliation notes; peers with high stock-based compensation or complex capital structures typically show higher volumes of these excluded securities.
jnj_antidilutive_securities_excluded_from_eps| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 1M | 1M | 1M | 2M | 3M | 3M | 3M | 5M | 7M | 6M | 6M | 15M | 8M | 4M | 6M | 6M | 13M | 16M | 12M | 18M |
| QoQ Change | — | +0.0% | +0.0% | +100.0% | +50.0% | +0.0% | +0.0% | +66.7% | +40.0% | -14.3% | +0.0% | +150.0% | -46.7% | -50.0% | +50.0% | +0.0% | +116.7% | +23.1% | -25.0% | +50.0% |
| YoY Change | — | — | — | — | +200.0% | +200.0% | +200.0% | +150.0% | +133.3% | +100.0% | +100.0% | +200.0% | +14.3% | -33.3% | +0.0% | -60.0% | +62.5% | +300.0% | +100.0% | +200.0% |